Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.
A double-blind, placebo-controlled trial was performed to analyse the ability of Lactobacillus plantarum 299v to prevent further recurrent episodes of Clostridium difficile-associated diarrhoea (RCDAD). Recurrence of clinical symptoms (main outcome) was seen in 4 of 11 patients who received metronidazole in combination with L. plantarum 299v and in 6 of 9 treated with metronidazole in combination with placebo. The lactobacilli treatment had no side-effects. Although the small sample size does not allow any conclusion to be drawn concerning the efficacy of L. plantarum in patients with RCDAD, these results may contribute to the ongoing discussion about the benefits of probiotics in patients with RCDAD and encourage the performance of larger multicentre studies.
Wullt
Marlene
M
Department of Infectious Diseases, University Hospital Malmö, Malmö, Sweden. marlene.wullt@skane.se
Hagslätt
Marie-Louise Johansson
ML
Odenholt
Inga
I
D000368:Aged; D016360:Clostridioides difficile / Q000502:physiology*; D004311:Double-Blind Method; D004761:Enterocolitis, Pseudomembranous / Q000628:therapy*; D005260:Female; D006801:Humans; D007778:Lactobacillus / Q000502:physiology*; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D019936:Probiotics / Q000627:therapeutic use*; D012008:Recurrence
D008795:Metronidazole